Surgicel® Original

DEVICE3 trials

Sponsors

Takeda, GATT Technologies BV

Conditions

BleedingGallbladder DiseasesHemorrhageHemorrhage, SurgicalIntraoperative BleedingLiver Diseases

Phase 3

TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery

CompletedNCT01192022

TakedaHemorrhage

Start: 2010-08-31End: 2013-05-31Updated: 2015-11-25

Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery

CompletedNCT01500135

Start: 2012-03-31End: 2015-12-31Updated: 2017-02-08

Unknown Phase

GATT-Patch Versus SURGICEL® Original in Minimally Invasive Liver and Gallbladder Surgery

CompletedNCT05900037

GATT Technologies BVGallbladder Diseases, Hemorrhage, Surgical, Intraoperative Bleeding +1

Start: 2023-10-02End: 2025-08-05Updated: 2026-02-12

Related Papers

Fibrin Sealant Patch (TachoSil) vs Oxidized Regenerated Cellulose Patch (Surgicel Original) for the Secondary Treatment of Local Bleeding in Patients Undergoing Hepatic Resection: A Randomized Controlled Trial

Journal of the American College of Surgeons2015-12-1876 citations